A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease

International Journal of STD and AIDS

Volumn 20, Issue 10, 2009, Pages 690-695

  Heystek, M ^a   Ross, J D C ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Whittall Street Clinic ^*  (United Kingdom)

Author keywords

Ciprofloxacin; Doxycycline; Metronidazole; Moxifloxacin; Pelvic inflammatory disease

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; METRONIDAZOLE; MOXIFLOXACIN;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; ARTICLE; ASTHENIA; BACTERIUM ISOLATION; CANDIDIASIS; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; NEISSERIA GONORRHOEAE; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ACUTE DISEASE; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DOUBLE-BLIND METHOD; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METRONIDAZOLE; PELVIC INFLAMMATORY DISEASE; QUINOLINES; TREATMENT OUTCOME;

EID: 70350241236     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008495     Document Type: Article

References (27)

1. Ross JDC, Judlin P, Nilas L. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS 2007;18:662-666 (Pubitemid 351738895)
2. Royal College of Obstetricians and Gynaecologists. Management of Acute Pelvic Inflammatory Disease. 2003; RCOG Guideline No. 32: 9pp
3. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2006. MMWR 2006;55:56-61
4. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol 1995;102:407-414
5. Bevan CD, Ridgeway GI, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003;31:45-54
6. Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol 1994;170:1008-1014 (Pubitemid 24157911)
7. Paavonen J, Teisala K, Heinonnen PK. Microbiological and histopathological findings in acute pelvic inflammatory disease. Br J Obstet Gynaecol 1987;94:454-460 (Pubitemid 17068096)
8. Westrom L, Joesoel R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility: a cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992;19:185-192
9. Haggerty CL. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. Curr Opin Infect Dis 2008;21:65-69
10. CDC. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. JAMA 2007;297:2466-2468
11. Centers for Disease Control and Prevention: pelvic inflammatory disease. 1998 Guidelines for the treatment of sexually transmitted diseases. MMWR 1998;47:79-85
12. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997;41:101-106
13. Aldrige KE, Ashcraft DS. Comparison of the in-vitro activities of BAY 12-8039, a new quinolone and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother 1997;41:709-711 (Pubitemid 27098431)
14. Donati M, Rodriguez Fermepin M, Olmo A, D'Apote L, Cevenini R. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J Antimicrob Chemother 1997;43:825-827
15. Hager WD, Eschenbach DA, Spence MR, Sweet RL. Criteria for diagnosis and grading of salpingitis. Obstet Gynecol 1983;61:113-114
16. Thomson SE, Hager WD, Wong KH, et al. The microbiology and therapy of acute pelvic inflammatory disease in hospitalized patients. Am J Obstet Gynecol 1980;136:179-186 (Pubitemid 10160320)
17. Hemsell DL, Solomokin JS, Sweet RL, Tally F, Bartlett JG, Carbon C. General Guidelines for the Evaluation of Pelvic Inflammatory Disease in Hospitalized Women. Beam TR, Gilbert DN, Kunin CM, eds. European Society of Chemotherapy and Infectious Diseases. 1993:70-80
18. Martens MG, Gordon S, Yarborough DR, Faro S, Binder D, Berkeley A. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. South Med J 1993;86:604-610 (Pubitemid 23183177)
19. Wendel GD, Cox SM, Bawdon RE, Theriot SK, Heard MC, Nobles BJ. A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. Am J Obstet Gynecol 1991;164:1390-1396
20. Peipert JF, Sweet RL, Walker CK, Kahn J, Reilly-Gauvin K. Evaluation of ofloxacin in the treatment of laparoscopically documented acute pelvic inflammatory disease (salpingitis). Infect Dis Obstet Gynecol 1999;7:138-144 (Pubitemid 29244767)
21. Ross JDC, Cronje HS, Paszkowski T, et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicenter, double blind, randomised trial. Sex Trans Infect 2006;82:446-451 (Pubitemid 46025184)
22. Felmingham D, Robbins M, Leakey A, et al. In vitro activity of moxifloxacin (BAY 12-8039), a novel 8-methoxyquinolone, compared with ofloxacin and other antibiotics. In: Adam D, et al., eds. Moxifloxacin in Practice. Vol.1. Oxford, UK: Maxim Medical, 1999:27-37
23. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999;43(Suppl B):1-11
24. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic inflammatory disease Evaluation And Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol 2002;186:929-937
25. Gronowski AM, Copper S, Baorto D, Murray PR. Reproducibility problems with the Abbott Laboratories LCx assay for Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microb 2000;38:2416-2418 (Pubitemid 30414382)
26. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Year 2007 Report. Health Protection Agency, London, 2007
27. European Medicines Agency Committee for Medicinal Products for Human Use Document reference EMEA/CHMP/524251/2008. Available at: http:// www.emea.europa.eu/pdfs/human/referral/avelox/moxifloxacin-avelox-bi-en.pdf (last checked November 2008)